Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gallic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | FUT7 | Q11130 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | CA3 | P07451 | 1/20 | 0.56 |
| ▸ | SELL | P14151 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | SELP | P16109 | 1/20 | 0.56 |
| ▸ | FUT4 | P22083 | 1/20 | 0.56 |
| ▸ | CA4 | P22748 | 1/20 | 0.56 |
| ▸ | CA6 | P23280 | 1/20 | 0.56 |
| ▸ | DPP4 | P27487 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | CA5A | P35218 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gallic Acid SCHEMBL21273260 | 1.00 | KDM4E (0.56) | KDM4ELMNATDP1ALDH1A1MAPT | |
| Gallic Acid SCHEMBL28331288 | 0.97 | KDM4E (0.54) | KDM4ELMNATDP1ALDH1A1MAPT | |
| Gallic Acid SCHEMBL4276877 | 0.97 | KDM4E (0.54) | KDM4ELMNATDP1ALDH1A1MAPT | |
| Gallic Acid SCHEMBL27661466 | 0.97 | KDM4E (0.54) | KDM4ELMNATDP1ALDH1A1MAPT | |
| Gallic Acid SCHEMBL1534149 | 0.97 | KDM4E (0.54) | KDM4ELMNATDP1ALDH1A1MAPT | |
| Gallic Acid SCHEMBL28693531 | 0.97 | KDM4E (0.54) | KDM4ELMNATDP1ALDH1A1MAPT | |
| Gallic Acid SCHEMBL28704045 | 0.97 | KDM4E (0.54) | KDM4ELMNATDP1ALDH1A1MAPT | |
| Gallic Acid SCHEMBL3134813 | 0.97 | KDM4E (0.54) | KDM4ELMNATDP1ALDH1A1MAPT | |
| Gallic Acid SCHEMBL28045481 | 0.97 | KDM4E (0.54) | KDM4ELMNATDP1ALDH1A1MAPT | |
| Gallic Acid SCHEMBL28654164 | 0.97 | KDM4E (0.59) | KDM4ELMNATDP1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 428 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024022447-A1 | USE OF BISMUTH-POLYMER COMPLEX IN DIGESTIVE TRACT VISUALIZATION | 上海交通大学 | 2024-02-01 | — | — | WO | claimed |
| WO-2023063827-A1 | SYNERGISTIC COMPOSITION AGAINST PSEUDOMONAS AERUGINOSA | OMNICIN THERAPEUTICS B.V. (NL) | 2023-04-20 | — | — | WO | claimed |
| CN-112267306-A | Flame-retardant anti-static fabric and preparation method thereof | 李东靖 | 2021-01-26 | — | — | CN | claimed |
| US-20200268769-A1 | METHODS FOR TREATING HELICOBACTER INFECTION | DEXCEL PHARMA TECHNOLOGIES LTD. (IL) | 2020-08-27 | — | — | US | claimed |
| EP-3541368-A1 | IMAGEABLE PARTICLES, METHODS OF MAKING AND METHODS OF USE THEREOF | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2019-09-25 | — | — | EP | claimed |
| EP-3036194-B1 | OPTICAL COMPOUNDS, USE AND METHOD FOR PRODUCING THEREOF | BEP S R L (IT) | 2019-03-27 | — | — | EP | claimed |
| WO-2018093566-A1 | IMAGEABLE PARTICLES, METHODS OF MAKING AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-05-24 | — | — | WO | claimed |
| US-9816029-B2 | Organic amine decarbonization solutions | CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2017-11-14 | — | — | US | claimed |
| EP-2768936-B1 | FORMULATIONS, THEIR USE AS OR FOR THE MANUFACTURE OF DISHWASHING COMPOSITIONS, AND MANUFACTURE | BASF SE (DE) | 2017-03-01 | — | — | EP | claimed |
| WO-2016203431-A1 | LUMINESCENT BISMUTH SILICATES, USE AND METHOD FOR PRODUCING THEREOF | UNIVERSITA' CA' FOSCARI (IT) | 2016-12-22 | — | — | WO | claimed |
| US-20020068836-A1 | Reaction systems for making N- (phosphonomethyl) glycine compounds | MONSANTO COMPANY | 2002-06-06 | — | — | US | claimed |
| US-20020016503-A1 | Use of a supplemental promoter in conjunction with a carbon-supported, noble-metal containing catalyst in liquid phase oxidation reactions | MONSANTO TECHNOLOGY LLC | 2002-02-07 | — | — | US | claimed |
| WO-2001092272-A2 | REACTION SYSTEMS FOR MAKING N-(PHOSPHONOMETHYL)GLYCINE COMPOUNDS | MONSANTO TECHNOLOGY LLC (US) | 2001-12-06 | — | — | WO | claimed |
| EP-0910393-B1 | AGENT FOR THE TOPICAL TREATMENT OF SKIN CONDITIONS | LUFEN HANS (DE) | 2001-12-05 | — | — | EP | claimed |
| WO-2001046208-A2 | USE OF A SUPPLEMENTAL PROMOTER IN CONJUNCTION WITH A CARBON-SUPPORTED, NOBLE-METAL-CONTAINING CATALYST IN LIQUID PHASE OXIDATION REACTIONS | MONSANTO TECHNOLOGY LLC (US) | 2001-06-28 | — | — | WO | claimed |
| CN-1238694-A | Composition containing bismuth and NSAID for treating gastrointestinal diseases | PROCTER & GAMBLE (US) | 1999-12-15 | — | — | CN | claimed |
| CN-1219390-A | Novel pharmaceutical composition for control and treatment of anorectal and colonic diseases | PANACEA BIOTEC LTD (IN) | 1999-06-16 | — | — | CN | claimed |
| US-5035973-A | Image forming method and apparatus therefor | KABUSHIKI KAISHA TOSHIBA (JP) | 1991-07-30 | — | — | US | claimed |
| US-4670245-A | ULCERS | VASQUEZ TONY E | 1987-06-02 | — | — | US | claimed |
| US-4298003-A | System for delivering agent at zero order rate with emerging agent below saturation | ALZA CORPORATION (US) | 1981-11-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016503-A1 | Use of a supplemental promoter in conjunction with a carbon-supported, noble-metal containing catalyst in liquid phase oxidation reactions | GNMT, OGG1, NT5C3B | KDM4E 1002/4885LMNA 875/4885TDP1 1320/4885 |
| US-20020068836-A1 | Reaction systems for making N- (phosphonomethyl) glycine compounds | GNMT, NPM1, OGA | KDM4E 4698/4885LMNA 1124/4885TDP1 2075/4885 |
| US-20200268769-A1 | METHODS FOR TREATING HELICOBACTER INFECTION | FUS, SI, NSF | KDM4E 4498/4885LMNA 3404/4885TDP1 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.